AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
AFT Leaves X Over AI-Generated Images of Minors 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
CLEVELAND, March 29, 2017 -- Athersys, Inc. (NASDAQ:ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present a corporate overview at the 16th Annual Needham Healthcare Conference at The Westin New York Grand Central Hotel in New York City. The presentation is scheduled for Tuesday, April 4, 2017 at 12:10 pm ET.
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website at www.athersys.com. An archived replay of the webcast will be available for 90 days on the Company's website after the conference.
About Athersys
Athersys is an international biotechnology company engaged in the development of therapeutic products designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.
ATHX-G
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected] David Schull Russo Partners, LLC Tel: (212) 845-4271 or (858) 717-2310 [email protected] Investor Contact: Peter Vozzo Westwicke Partners (443) 213-0505 or (443) 377-4767 (mobile) [email protected]
